JP2022525651A5 - - Google Patents

Info

Publication number
JP2022525651A5
JP2022525651A5 JP2021556400A JP2021556400A JP2022525651A5 JP 2022525651 A5 JP2022525651 A5 JP 2022525651A5 JP 2021556400 A JP2021556400 A JP 2021556400A JP 2021556400 A JP2021556400 A JP 2021556400A JP 2022525651 A5 JP2022525651 A5 JP 2022525651A5
Authority
JP
Japan
Prior art keywords
cells
gene
genetically modified
hiv
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021556400A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022525651A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/023117 external-priority patent/WO2020190925A1/en
Publication of JP2022525651A publication Critical patent/JP2022525651A/ja
Publication of JP2022525651A5 publication Critical patent/JP2022525651A5/ja
Priority to JP2024163218A priority Critical patent/JP2024175115A/ja
Pending legal-status Critical Current

Links

JP2021556400A 2019-03-19 2020-03-17 Cd4欠損car t細胞および抗cd4 car t細胞を作製するための方法および組成物ならびにその使用 Pending JP2022525651A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024163218A JP2024175115A (ja) 2019-03-19 2024-09-20 Cd4欠損car t細胞および抗cd4 car t細胞を作製するための方法および組成物ならびにその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962820387P 2019-03-19 2019-03-19
US62/820,387 2019-03-19
PCT/US2020/023117 WO2020190925A1 (en) 2019-03-19 2020-03-17 Methods and compositions for engineering cd4-deficient car t cells and anti-cd4 car t cells and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024163218A Division JP2024175115A (ja) 2019-03-19 2024-09-20 Cd4欠損car t細胞および抗cd4 car t細胞を作製するための方法および組成物ならびにその使用

Publications (2)

Publication Number Publication Date
JP2022525651A JP2022525651A (ja) 2022-05-18
JP2022525651A5 true JP2022525651A5 (cg-RX-API-DMAC7.html) 2024-01-30

Family

ID=72519342

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021556400A Pending JP2022525651A (ja) 2019-03-19 2020-03-17 Cd4欠損car t細胞および抗cd4 car t細胞を作製するための方法および組成物ならびにその使用
JP2024163218A Pending JP2024175115A (ja) 2019-03-19 2024-09-20 Cd4欠損car t細胞および抗cd4 car t細胞を作製するための方法および組成物ならびにその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024163218A Pending JP2024175115A (ja) 2019-03-19 2024-09-20 Cd4欠損car t細胞および抗cd4 car t細胞を作製するための方法および組成物ならびにその使用

Country Status (4)

Country Link
US (1) US12703735B2 (cg-RX-API-DMAC7.html)
EP (1) EP3941486A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022525651A (cg-RX-API-DMAC7.html)
WO (1) WO2020190925A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025504343A (ja) * 2021-12-30 2025-02-12 重▲慶▼精准生物技▲術▼有限公司 ユニバーサルcar-t細胞の調製技術及びその使用
CN116410932A (zh) * 2021-12-30 2023-07-11 重庆精准生物技术有限公司 一种通用型car-t细胞的制备方法及其应用
CN116410931A (zh) * 2021-12-30 2023-07-11 重庆精准生物技术有限公司 一种通用型car-t细胞的制备技术及其应用
CN118662607B (zh) * 2023-03-15 2026-07-07 中国科学院上海药物研究所 抑制过激炎性反应的蛋白及其应用
WO2026032970A1 (en) * 2024-08-07 2026-02-12 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Cd4-specific chimeric antigen receptor and methods and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710169B2 (en) * 1987-10-02 2004-03-23 Genentech, Inc. Adheson variants
EP3027755B1 (en) 2013-08-02 2019-10-09 The Regents of The University of California Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
SG10201808811QA (en) 2014-04-10 2018-11-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Method and compositions for cellular immunotherapy
WO2015167766A1 (en) 2014-04-29 2015-11-05 Seattle Children's Hospital (dba Seattle Children's Research Institute) Ccr5 disruption of cells expressing anti-hiv chimeric antigen receptor (car) derived from broadly neutralizing antibodies
ES2836743T3 (es) 2014-06-02 2021-06-28 Us Health Receptores de antígeno quiméricos que seleccionan como diana CD-19
CA2977106A1 (en) * 2015-02-27 2016-09-01 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
US10648020B2 (en) 2015-06-18 2020-05-12 The Broad Institute, Inc. CRISPR enzymes and systems
MX2018001568A (es) 2015-08-07 2019-04-25 Seattle Children´S Hospital Dba Seattle Children´S Res Institute Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos.
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
WO2017044776A1 (en) * 2015-09-10 2017-03-16 Texas Tech University System Single-guide rna (sgrna) with improved knockout efficiency
US20180371052A1 (en) 2015-12-22 2018-12-27 Icell Gene Therapeutics Llc Chimeric antigen receptors and enhancement of anti-tumor activity
MX2018010484A (es) 2016-03-04 2019-01-10 Editas Medicine Inc Métodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cáncer.
WO2017172952A1 (en) 2016-04-01 2017-10-05 Promab Biotechnologies, Inc. Flag tagged cd19-car-t cells
US12350349B2 (en) 2016-08-03 2025-07-08 Washington University Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors
WO2019106522A1 (en) * 2017-11-28 2019-06-06 Novartis Ag Pooled crispr/cas9 screening in primary cells using guide swap technology

Similar Documents

Publication Publication Date Title
AU2022271376B9 (en) CRISPR/CAS-related methods and compositions for treating herpes simplex virus
EP4176048B1 (en) Genetically engineered t cells with regnase-1 and/or tgfbrii disruption have improved functionality and persistence
JP7252328B2 (ja) Rnaを編集する方法および組成物
Dabiri et al. Site-specific transgene integration in chimeric antigen receptor (CAR) T cell therapies
JP6929791B2 (ja) エピゲノム編集のための組成物および方法
JP7553440B2 (ja) 抗cd33免疫細胞癌療法
JP2023055884A5 (cg-RX-API-DMAC7.html)
JP2024097924A (ja) 抗ptk7免疫細胞癌療法
JP7471289B2 (ja) 抗liv1免疫細胞癌療法
JP2021518102A5 (cg-RX-API-DMAC7.html)
JP2016520319A5 (cg-RX-API-DMAC7.html)
JP2021518162A5 (cg-RX-API-DMAC7.html)
JP2022519595A5 (cg-RX-API-DMAC7.html)
RU2019133280A (ru) Композиции и способы для иммуноонкологии
JP2021518160A5 (cg-RX-API-DMAC7.html)
JP2022521787A (ja) Rna誘導型エンドヌクレアーゼを使用するdna組み込みのための改善された方法
JP2021502077A5 (cg-RX-API-DMAC7.html)
JP2024511131A5 (cg-RX-API-DMAC7.html)
JP2022525651A (ja) Cd4欠損car t細胞および抗cd4 car t細胞を作製するための方法および組成物ならびにその使用
TW202417626A (zh) 具有共表現的tgfbr shrna之免疫細胞
KR102264115B1 (ko) 무-운반체 다중 CRISPR/Cas 9 유전자 편집 복합체 및 그의 용도
CN118871583A (zh) 修饰的基于crispr的基因编辑系统及其使用方法
JP2020513849A5 (cg-RX-API-DMAC7.html)
AU2018231559A1 (en) Extracellular matrix-producing composition using MAST4 gene and preparation method therefor
US11053503B2 (en) Methods and means of generating IL-17 associated antitumor effector cells by inhibition of NR2F6 inhibition